Podcasts about Pharma

At 25, Jace Yawnick was building a career in health and wellness sales, chasing growth, status, and the usual young adult fantasy of getting somewhere fast. Then his body stopped cooperating. Fatigue turned into chemotherapy. The diagnosis was primary mediastinal B cell non Hodgkin lymphoma, and the rest of his life split into before and after. Now in remission, he talks about cancer the way people actually live it, not the way nonprofits package it. He gets into survivorship, mental health, young adult isolation, and the deadening absurdity of prior authorization. One of the sharpest parts of the conversation lands on a simple American insult disguised as policy: treatment innovation means very little when insurance can still deny the scan, the drug, or the next step. Jace has seen that firsthand, including during routine monitoring after active treatment. This episode tracks what happens when a young cancer patient becomes a public voice and refuses to play mascot. It covers oncology, insurance, remission, advocacy, and the long mental hangover that follows survival. It also names the part too many institutions dodge: the system works great right up until it doesn't, and when it fails, patients get handed the bill, the panic, and a camera if they want anyone to care. RELATED LINKSJace Beats CancerJace Yawnick on LinkedImConquer Cancer ArticleCURE Today ArticlePyure BrandsFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The future of market access belongs to organizations that plan years in advance. In this episode, Steve Mather, Global Practice Lead of Strategy and Insight at Lumanity, explains why pharmaceutical companies must prepare now for major market access changes coming in Europe and beyond. He highlights that Joint Clinical Assessments for rare disease assets, beginning in 2028, will require earlier planning, stronger governance, and more integrated evidence-generation strategies. Steve also discusses the complexity created by varying country-specific care pathways, limited comparators, and the growing importance of real-world evidence in rare disease development. Across policy shifts like JCA, IRA, MFN, and new European pharmaceutical legislation, the central message is clear: organizations that anticipate earlier will be better positioned to succeed. Tune in to hear how the future of rare disease market access is being reshaped, and why companies that prepare earlier will have a major strategic advantage! Resources: Connect with and follow Steve Mather on LinkedIn. Follow Lumanity on LinkedIn and explore their website! Learn more about this series we're doing with Lumanity here:  https://lumanity.com/commercialization-podcasts/

In today's episode of The Daily Brief, we cover two major stories shaping the Indian economy and global markets: 00:04   Intro 00:25   Why medicine prices matter 13:08   Hotels bet on India 22:28   Tidbits We also send out a crisp and short daily newsletter for The Daily Brief. Put your email here and we'll make you smart every day: https://thedailybriefing.substack.com/ Note: This content is for informational purposes only. None of the stocks, brands, or products mentioned are recommendations or endorsements.

Pharma ads have a language of their own. See omnystudio.com/listener for privacy information.

Episode Notes **More than $200 billion in pharma revenue is at risk from patent expirations through 2030, and TA teams are caught in the middle. Reducing legacy field forces, staffing specialty launches, and opening reshored plants often happen at the same time, on systems that weren't built for any of it. In this episode of Talent Experience Live, we break down three of the highest-pressure hiring scenarios in pharma right now and show exactly which AI agents are helping TA teams run them in parallel — without burning out their recruiters or cutting corners on compliance.**

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of remarkable updates that highlight the dynamic evolution of drug development, regulatory landscapes, and industry strategies. Takeda has made waves with its TYK2 inhibitor, Zasocitinib, which recently outperformed Bristol Myers Squibb's Sotyktu in a pivotal Phase 3 trial for plaque psoriasis. This trial is particularly noteworthy as it involves TYK2 inhibitors, a class of drugs targeting tyrosine kinase 2 to modulate immune responses. The success of Zasocitinib not only strengthens Takeda's competitive position but also underscores the potential of these inhibitors in treating autoimmune conditions like psoriasis. As we look forward to its market launch next year, this development represents a significant stride in the realm of targeted therapies aimed at complex diseases. Shifting gears to regulatory advancements, Johnson & Johnson's Darzalex (daratumumab) has received endorsement from NICE for its quadruplet therapy in newly diagnosed transplant-ineligible multiple myeloma cases. This approval is based on favorable Phase 3 trial results and highlights the therapeutic potential of targeting CD38 on myeloma cells. This marks a crucial step in offering potent treatment options to patients who cannot undergo transplants, emphasizing the growing importance of combination therapies in oncology. In another significant development, Johnson & Johnson is expanding its rare disease portfolio with promising Phase 2/3 trial data for Imaavy. Poised to become the first approved treatment for warm autoimmune hemolytic anemia, this advancement highlights the industry's pivot towards addressing rare diseases with limited treatment options. In India, AstraZeneca has secured CDSCO approval for Enhertu (trastuzumab deruxtecan) combined with pertuzumab as a first-line treatment for HER2-positive unresectable or metastatic breast cancer. This approval signifies a milestone in HER2-targeted therapies, spotlighting the pivotal role of antibody-drug conjugates that deliver cytotoxic agents directly to cancer cells, enhancing efficacy while minimizing systemic exposure. Moving on to business developments, Servier's partnership with N-Lorem Foundation to develop antisense oligonucleotide therapies for rare neurological disorders reflects the industry's increasing focus on precision medicine. This collaboration underscores the burgeoning interest in nucleic acid-based therapies aimed at addressing genetic disorders lacking effective treatments. On the financial front, Kardigan's planned $320 million IPO signals robust confidence in advancing cardiovascular pipeline assets. This move highlights Kardigan's commitment to tackling substantial unmet needs in cardiovascular diseases—an area still rife with challenges despite existing therapies. From a regulatory perspective, China's update of its Good Clinical Practice guidelines aims to streamline clinical trial processes, fostering biotech innovation. This change is expected to enhance drug development efficiency and attract global biotech investments to China's rapidly growing pharmaceutical market. Meanwhile, Pfizer CEO Albert Bourla has raised concerns about Germany's healthcare reform plans, warning that they might deter future investments. His comments underscore the delicate balance between cost containment policies and maintaining an environment conducive to pharmaceutical innovation. Additionally, Novo Nordisk's CEO Mike Doustdar expressed optimism about the company's strategic focus on market positioning through innovation and efficiency improvements. This aligns with broader industry trends where large pharma companies strive to maintain leadership roles amid fierce competition. Eli Lilly's sponsorship of short films premiered at Tribeca Festival illustrates an industry-wide trend toward patient-centric approaches and authentic portrayals of people with diseases onscreen. Such efforts aim to enhance communication strategies that resonate with diverse audiences. Furthermore, transformative technologies like cell and gene therapies are gradually moving towards mainstream clinical adoption. This transition necessitates zero-tolerance logistics to ensure these complex therapies reach patients safely and effectively—a paradigm shift offering potential cures but also posing logistical challenges. Finally, industry events such as ASCO continue to spotlight cutting-edge research developments in oncology. Such conferences are pivotal in advancing treatment paradigms and fostering collaborations that drive innovation across the sector. These updates reflect a period marked by groundbreaking scientific advances and strategic initiatives poised to reshape patient care and global healthcare solutions. As companies navigate these complexities while addressing regulatory and economic challenges, maintaining a focus on innovation will be key in charting future growth trajectories within the pharmaceutical and biotech sectors.Support the show

Poolbeg Pharma has announced the activation of the first clinical trial site for its POLB 001 TOPICAL study, marking a key operational milestone for its lead programme. The trial will evaluate POLB 001 as a potential preventative treatment for Cytokine Release Syndrome in relapsed/refractory multiple myeloma patients receiving teclistamab, an approved bispecific antibody. With recruitment now underway and interim data expected in summer 2026, the study could provide an important early readout on POLB 001's role in improving the safety and accessibility of cancer immunotherapies.

Die Grüne Bundestagsabgeordnete Paula Piechotta fordert Änderungen bei Preisregeln für Medikamente, vor allem bei denen mit Patentschutz. Die Pharma-Lobby versuche immer wieder, die Bundesregierung zu erpressen.

Poolbeg Pharma PLC (AIM:POLB) principal scientist Liam Tremble joined Proactive's Stephen Gunnion to discuss the first site activation for Poolbeg's POLB 001 TOPICAL clinical trial, evaluating the drug as a preventative treatment for cytokine release syndrome (CRS), a serious side effect linked to CAR-T and bispecific antibody therapies. The UK study will enrol 30 multiple myeloma patients receiving teclistamab, with early readouts expected due to CRS typically occurring within the first two weeks of treatment. Tremble also highlighted new data presented at the EHA Congress showing POLB 001 reduced inflammatory cytokines without compromising tumour-killing activity, alongside early research suggesting potential applications in acute myeloid leukaemia (AMS). For more interviews and market insights, visit Proactive's YouTube channel. Don't forget to like this video, subscribe to the channel and enable notifications so you never miss future content. #PoolbegPharma #POLB001 #Biotech #MultipleMyeloma #AML #AcuteMyeloidLeukemia #CancerResearch #Immunotherapy #CRS #CytokineReleaseSyndrome #Teclistamab #BloodCancer #ClinicalTrials #EHA2026 #HealthcareInnovation

At 20 years old, newly arrived from Puerto Rico and trying to build a future in science, Benjamin Suarez Jimenez found himself sitting in front of two senior faculty members accused of plagiarism. He knew the material. He had done the work. His mistake came from failing to cite class notes during an exam because nobody had told him that was expected. In a matter of minutes, he watched what felt like his entire career flash before him.On this episode of Standard Deviation, host Oliver Bogler examines the hidden architecture of academic science through the experiences of Dr. Benjamin Suarez Jimenez, Assistant Professor at the University of Rochester and a neuroscientist studying PTSD, anxiety, trauma, and spatial cognition through virtual reality and video game environments.Benjamin traces his path from Puerto Rico to the mainland United States, through the NIH, Columbia University, and eventually to leading his own laboratory. Along the way, he encountered a series of barriers that had little to do with scientific ability and everything to do with access to unwritten rules. From academic gatekeeping to grant writing expectations, he learned that success in biomedical research often depends on knowledge that never appears in a textbook.Oliver explores how those invisible obstacles shape careers, influence research funding, and determine who gains access to opportunity. The conversation also examines the Justice, Equity, Diversity, and Inclusion Program at the Life Science Editors Foundation, which pairs scientists from underrepresented backgrounds with experienced scientific editors. Through that mentorship, Benjamin transformed a critical grant proposal into a successful pilot award that helped launch an NIH R01 application.The discussion extends beyond one scientist's experience. Benjamin describes helping a former mentee navigate dissertation roadblocks that threatened her graduation, illustrating how institutional bureaucracy can delay careers and discourage talented researchers. Together, they explore the hidden administrative burden, cultural barriers, and bias that many scientists carry alongside their research, and what happens when someone who receives support turns around and opens the door for others.RELATED LINKSLife Science Editors FoundationBenjamin Suarez Jimenez LabDr. Benjamin Suarez JimenezBenjamin Suarez JimenezFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

No dilly-dallying around if you want reduced sutures on your drugs. Applications to lower 100% tariffs are due tomorrow. Listen for more on Two Minutes in Trade. 

AI is moving incredibly fast across the life sciences sector, but many organizations still struggle to build systems that deliver real operational value. In this episode, tech leader Rose LaRocca-Fisch explains why strong data governance and business alignment must come before chasing software trends. Please visit our website to get more information: https://swangroup.net/ Rose shares her practical leadership experience guiding pharmaceutical companies, CDMOs, and global biotech organizations through massive growth. The discussion breaks down why high-profile tech implementations collapse and outlines the exact steps needed to prepare your infrastructure for enterprise-grade tools.Key themes covered in this conversation:Why does advanced software amplify existing operational flaws instead of fixing themThe OASIS framework for sustainable and scalable IT transformationHow data readiness directly impacts clinical trial success and manufacturing yieldsReal-world applications using platforms like Databricks to speed up patient enrollmentThe shift toward AI-assisted work and managing data integrity risksLinks from this episode:Get to know more about Steven Swan: https://www.linkedin.com/in/swangroup Get to know more about Rose LaRocca-Fisch: https://www.linkedin.com/in/rose-larocca-fisch 

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The pharmaceutical and biotech industries are undergoing significant transformations, driven by scientific advancements, regulatory changes, and strategic investments. These developments are shaping the landscape of drug development and patient care in profound ways. In recent news, Pfizer's CEO, Albert Bourla, is reconsidering investments in Germany due to proposed healthcare reforms. These reforms have sparked concerns about their potential impact on the pharmaceutical industry. This situation highlights the intricate balance between regulatory frameworks and corporate strategies, illustrating how policy changes can influence investment decisions and operational strategies within the pharma sector. The tension between regulatory environments and corporate interests is a recurring theme that continues to shape strategic directions within the industry. Meanwhile, heightened scrutiny over biotechnology operations is evident with Wuxi AppTec's inclusion on the Pentagon's blacklist under the Biosecure Act. This move reflects growing concerns about biosecurity and the necessity for stringent oversight in handling sensitive biotechnological advancements. Such actions underscore a global focus on safeguarding national security while fostering scientific innovation. Teva Pharmaceuticals is navigating restructuring efforts by laying off 250 employees at its Active Pharmaceutical Ingredients unit as it seeks a new owner. This restructuring underscores the challenges companies face in maintaining operational efficiency amid ownership transitions. These challenges are emblematic of broader industry dynamics where companies strive to adapt to changing market conditions while ensuring stability and growth. On the scientific front, Novo Nordisk's cagrisema and Eli Lilly's retatrutide are emerging as next-generation incretin therapies. Although early comparisons have been made, Novo Nordisk's chief scientific officer suggests it is premature to declare a definitive leader. This competition reflects the dynamic nature of drug development as companies strive to innovate and improve treatment options continuously. Additionally, Sonothera's successful $125 million Series B funding round for its bubble-based genetic delivery system highlights the biotech industry's momentum fueled by mergers and acquisitions (M&A) and partnerships. Such technologies promise to advance genetic therapies by enhancing delivery mechanisms, potentially transforming treatment paradigms for various genetic disorders. AbbVie's Skyrizi narrowly surpassing Johnson & Johnson's Tremfya in May drug ad spending underscores the competitive nature of pharmaceutical marketing. Despite a general slump in advertising expenditures among leading drugs, strategic marketing remains crucial for maintaining brand presence and market share. Increased M&A activity and partnerships are further bolstering the industry's growth trajectory. The resurgence of Initial Public Offerings (IPOs) and venture capital funding is fostering innovation and expansion within the sector, providing fuel for continued advancement in biotech. On the regulatory front, Johnson & Johnson's Darzalex received a new endorsement from NICE after a prior reversal. Such regulatory updates emphasize the evolving nature of drug approvals and market access strategies essential for pharmaceutical companies' success. Novartis' second deal with Orionis Biosciences worth up to $1.4 billion exemplifies strategic investments aimed at expanding research capabilities and addressing unmet medical needs through molecular glue technologies targeting challenging therapeutic areas. Conversely, Sanofi's decision to halt a Phase 3 autoimmune trial due to insufficient efficacy highlights the inherent risks in drug development pipelines. These setbacks emphasize the importance of robust clinical trial designs and adaptability in R&D strategies. Emerging insights into GLP-1 drugs like Novo Nordisk's semaglutide reveal potential antidepressant effects linked to gut microbiota modulation. These findings open new avenues for exploring psychiatric applications of metabolic drugs, although conflicting data necessitates further investigation. Overall, these developments illustrate a complex interplay of scientific innovation, regulatory dynamics, and strategic corporate actions driving the future of pharmaceuticals and biotechnology. The sector continues to navigate challenges while capitalizing on opportunities to enhance patient care through advanced therapeutic solutions. The industry's trajectory promises transformative impacts on patient care through novel therapies designed not only to treat symptoms but also address root causes via innovative science-driven solutions. As these advancements unfold, they herald a new era of targeted, effective treatments that hold promise for improving patient outcomes across diverse medical landscapes.Support the show

In this episode of SCW for Pharma, Evren Ozkaya welcomes Rajeev Kumar, Vice President at Biological E. Limited, a leading vaccine manufacturer and CDMO. Drawing on nearly three decades of experience across pharmaceutical manufacturing, supply chain management, and digital excellence, Rajeev shares his perspective on the evolution of the Indian pharmaceutical industry and the growing importance of quality, compliance, and digitalization.The conversation begins with Rajeev reflecting on how pharmaceutical manufacturing has changed since he entered the industry in the late 1990s. He explains that early pharmaceutical production focused heavily on antibiotics and APIs, where processes were comparatively straightforward and compliance requirements were less demanding. As the industry shifted toward vaccines, biologics, and other complex therapies, manufacturers faced significantly greater expectations around batch validation, data integrity, and audit readiness.Evren and Rajeev then explore the competitive advantages that have helped India become a global pharmaceutical powerhouse. While lower labor costs and large-scale manufacturing capabilities have historically contributed to India's success, Rajeev argues that the industry's strength today extends beyond cost leadership. He highlights India's growing expertise in producing complex biologics and vaccines at scale, supported by a highly skilled workforce and strong engineering capabilities.The discussion then turns to digital transformation and its role in improving productivity and reducing manufacturing costs. Rajeev explains that for advanced products such as mRNA vaccines and biologics, reproducible processes are essential. Monitoring yield, quality, and operational performance in real time requires digital technologies that support consistent execution and data-driven decision-making. He notes that while India continues to maintain cost advantages, future competitiveness will increasingly depend on talent, innovation, and manufacturing excellence.In the second half of the conversation, Rajeev provides a practical introduction to ALCOA+, one of the foundational frameworks for pharmaceutical data integrity. He explains the principles of Attributable, Legible, Contemporaneous, Original, and Accurate data, along with the additional requirements that data must be Complete, Consistent, Enduring, and Available. Rajeev demonstrates how technologies such as electronic batch records, digital logbooks, e-signatures, automated data collection, IoT connectivity, and cloud-based systems help manufacturers satisfy these requirements while improving operational efficiency.The discussion highlights an important connection between compliance and productivity. Rajeev explains that high-quality, automated data not only supports regulatory requirements but also enables better decision-making across manufacturing operations. As a result, investments in digital technologies often create benefits that extend far beyond compliance alone.Finally, Evren and Rajeev examine the future of digitalization in pharmaceutical manufacturing. While many companies still rely heavily on paper-based processes, Rajeev believes manufacturers must adopt digital transformation strategies that align with their level of digital maturity. Looking ahead, he suggests that as regulatory expectations continue to evolve, technologies such as digital logbooks and electronic batch records may become increasingly necessary—and potentially mandatory—for maintaining compliance and meeting future GMP requirements.Evren and Rajeev conclude their insightful conversation by emphasizing that quality, compliance, and digital transformation are becoming inseparable. As pharmaceutical manufacturing continues to advance toward more complex therapies, organizations that combine strong data integrity practices with modern digital technologies will be best positioned to achieve both regulatory excellence and operational performance.

Pharma commercial teams are generating more data than ever, but field intelligence is still arriving too late to change rep behavior before the engagement window closes. In this episode, Damion Nero, Global Head of Statistics at Daiichi Sankyo, joins Emerj editor Yolandi de Weerdt to examine why fragmented data pipelines, not a shortage of data, are the structural root of the gap between commercial insight and field execution. The conversation covers what separates teams that successfully adopt AI from those stuck in the pilot phase, and why starting with routine, high-certainty use cases consistently produces more commercial lift than chasing ambitious automation. This episode is sponsored by ODAIA. Learn how leading organizations approach AI investment more like a venture portfolio, and why interdisciplinary collaboration is critical to defining the right data for AI success. Download our free PDF report, "Beginning with AI," at emerj.com/aik1

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The landscape of these industries is one of constant evolution, characterized by scientific advancements, strategic mergers, and regulatory maneuvers that shape the future of healthcare. In a significant scientific breakthrough, Merck & Co. and Gilead Sciences have made strides in HIV treatment with the development of a weekly pill. This innovative regimen combines Merck's islatravir with Gilead's lenacapavir, showing promise in two phase 3 trials. If approved, this long-acting oral therapy could revolutionize HIV care by offering a more convenient dosing schedule, potentially improving patient adherence and outcomes substantially. This novel regimen signifies progress towards simplifying HIV treatments with once-weekly dosing. Meanwhile, in the oncology sector, Gilead's Trodelvy faced challenges when combined with Merck's Keytruda as a first-line treatment for PD-L1-high non-small cell lung cancer. The phase 3 EVOKE-03 trial was terminated, shifting attention to competitors like AstraZeneca and Daiichi Sankyo, who continue to advance their own therapies in this area. In a strategic move to bolster its position in lung cancer treatment, GlaxoSmithKline (GSK) is acquiring Nuvalent for $10.6 billion, aiming to secure near-approval cancer therapies capable of challenging market leaders like Roche and Pfizer. This acquisition underscores the focus on targeted cancer therapies that increase treatment efficacy by honing in on specific genetic markers. Nuvalent's innovative pipeline of small molecule inhibitors targets drug resistance and mutations in cancer treatment—a strategic addition to GSK's portfolio aimed at enhancing its position amidst rapid advancements and intense competition in oncology. In diabetes and obesity management, Eli Lilly is advancing with its new oral GLP-1 receptor agonist, Foundayo (orforglipron), which has shown competitive efficacy over oral semaglutide. Analysts see Lilly's progress as strengthening its leadership in the growing obesity drug market. Similarly, AstraZeneca is making progress with its own GLP-1 candidate, elecoglipron, as phase 2 data sets the stage for pivotal studies. Promising clinical trial data from Eli Lilly's retatrutide for obesity-related conditions and AstraZeneca's elecoglipron suggest a strengthening pipeline for GLP-1 receptor agonists known for their dual effects on weight management and glycemic control. On the diagnostics front, Roche reaffirms its €600 million investment in Germany amid industry retrenchments by companies like Eli Lilly and Boehringer Ingelheim. However, Roche remains cautious about future risks due to shifting economic conditions. The financial dynamics within biotech are also noteworthy. Parabilis Medicines is planning a potentially record-setting IPO following Kailera Therapeutics' successful public offering earlier this year. These trends indicate strong investor confidence and an influx of funding towards innovative cancer therapies. Meanwhile, CeQur's $100 million Series E funding round aims at accelerating insulin patch delivery systems' commercial growth—highlighting ongoing innovation in diabetes management solutions. Regulatory updates reveal AstraZeneca facing reprimands from the UK marketing watchdog due to repeated breaches related to LinkedIn activities—an ongoing challenge in pharmaceutical marketing compliance. The integration of digital health solutions continues apace as ixlayer partners with Vertex Pharmaceuticals to launch a digital acute pain management platform. This initiative aims at improving patient care by reducing reliance on opioid-based treatments. These developments paint a picture of an industry where scientific innovations, regulatory hurdles, and technological advancements intersect to shape future therapeutic landscapes. Precision oncology is another area witnessing substantial growth. The landscape also sees notable activity in rare disease therapeutics. Johnson & Johnson's Talvey has gained acceptance in Scotland for treating relapsed multiple myeloma using bispecific antibody technology—a trend toward leveraging immune system targeting technologies to enhance cancer treatment efficacy. Moreover, Zai Lab's Tivdak received approval from China's NMPA for cervical cancer treatment based on Phase 3 data, highlighting the rise of antibody-drug conjugates (ADCs) as potent oncology therapies due to their targeted delivery mechanisms. On the research collaboration front, AlzeCure Pharma's partnership with Eli Lilly focuses on Alzheimer's disease research through Alzstatin ACD680—a small molecule targeting neurodegenerative pathways—a testament to the collaborative efforts needed to tackle complex diseases like Alzheimer's. However, challenges persist as Bial discontinued its GCase activator program after failing Phase 2b trials for Parkinson's patients with GBA1 variants—a stark reminder of the high-risk nature inherent in drug development despite initial promise. These myriad developments underscore a vibrant period within pharmaceutical and biotech sectors where scientific advancements rapidly translate into actionable therapies promising substantial improvements in patient care by addressing unmet medical needs globally.Support the show

Dr. Sarah Matt trained as a burn surgeon, working in a field where patients arrive with catastrophic injuries and survival depends on speed, skill, and resources. She left the bedside after confronting a limit that medicine does not like to admit. One physician can only see so many people in a day. The system surrounding those patients decides the rest. She moved into health technology, held leadership roles in startups, and built global infrastructure at Oracle to scale care across populations. Then she watched billions of dollars in digital health and AI initiatives stall out when they hit real clinical environments.This episode follows that pivot from surgeon to strategist and back into direct patient care in rural New York, where she now treats uninsured patients, migrant workers, and communities pushed to the margins. The conversation centers on a persistent failure across healthcare systems. Products get built for regulators, executives, and investors instead of the people who use them. The result shows up in failed adoption, broken workflows, prior authorization delays, and rising physician burnout.The discussion cuts through health policy language and lands on lived consequence. The system rewards speed over usability, scale over trust, and compliance over care. Patients absorb the fallout. Physicians carry the liability. The incentives remain intact.RELATED LINKSDr. Sarah MattThe Borderless Healthcare RevolutionThe Clinical RealistJessica FedererSovatoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of The Executive Dose Podcast, host Stephen Beckman leads a timely discussion on how pharmaceutical manufacturers approach portfolio ideation, portfolio development, and strategic growth in today's increasingly complex healthcare environment.   Stephen is joined by Joe Hendrickson, Head of Strategy and Corporate Development for Serovia, for a conversation focused on how manufacturers identify unmet market needs, evaluate product opportunities, prioritize development pathways, and make strategic decisions amid growing industry pressure.   The discussion explores how pharmaceutical companies move from early-stage ideation to portfolio evaluation, development, commercialization, and lifecycle planning. As manufacturers face rising pricing pressure, market access barriers, regulatory expectations, competitive intensity, supply chain constraints, and evolving stakeholder demands, disciplined portfolio strategy has become more important than ever.   Listeners will gain perspective on how manufacturers are navigating uncertainty, adapting their growth strategies, and building more resilient portfolio models designed to bring meaningful therapies and solutions to market. Special Guest Joe Hendrickson Head of Strategy and Corporate Development Serovia

Join us as we preview the World Cup, the only way we know how, chaos and prop bets!

Interest in macrocyclic peptides (MCPs) continues to grow, which means manufacturers are facing mounting pressure to develop production methods capable of supporting commercial-scale demand of these molecules. While they offer a unique combination of potency, selectivity, and drug-like properties, the structural complexity of MCPs has historically made them difficult and costly to manufacture using traditional peptide synthesis techniques. As a result, new manufacturing approaches are emerging that aim to improve efficiency, scalability, and sustainability while expanding access to this promising class of therapeutics. In this episode of Off Script, we spoke with David Thaisrivongs, executive director, head of biocatalysis at Merck, about research recently published in Science detailing a biocatalytic manufacturing process for enlicitide, an investigational oral macrocyclic peptide designed to lower LDL cholesterol. The conversation explores the limitations of conventional solid-phase peptide synthesis, how Merck leveraged enzyme-driven manufacturing and crystallization strategies to significantly reduce process complexity, and why minimizing chromatography can be critical for commercial-scale peptide production. He also discussed the broader implications of biocatalysis for manufacturing increasingly complex therapeutic modalities and how the technology could help shape the future of pharmaceutical production.

US President Trump said they are negotiating with Iran, and a victory will happen very soon, while he stated they will declare total victory in two weeks.US President Trump said Israel and Iran agreed to leave each other alone for another week.US equity futures continue to gain; FTSE 100 underperforms as Pharma giants fall. DXY returns below 100.00 handle, Kiwi outperforms while GBP gains following strong BRC sales. Fixed income benchmarks are tentatively firmer as geopolitical tensions ease.Crude continues to soften amid halted Iran-Israeli strikes; metals supported by softer dollar and positive risk toneLooking ahead, highlights include Mexican Inflation (May), US ADP Weekly Change, Exports/Imports, Atlanta Fed GDP, Existing Home Sales (May), Wholesale Inventories (Apr), Canadian Exports/Imports (Apr), EIA STEO (Jun), Comments from ECB President Lagarde, Supply from the US.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're delving into a series of groundbreaking advancements and strategic movements reshaping the landscape of drug development and patient care. Eli Lilly's retatrutide has emerged as a significant breakthrough in obesity treatment, demonstrating a remarkable 30.3% weight reduction over two years in a Phase 3 trial. This drug, a triple agonist targeting glucagon-like peptide-1 receptors, regulates appetite and energy balance effectively. Such results not only highlight its potential as a transformative therapy for obesity but also position Eli Lilly prominently within metabolic disorder treatment landscapes. With global obesity rates on the rise, retatrutide's success could meaningfully impact public health strategies and pharmaceutical approaches to managing weight. In the oncology sector, Johnson & Johnson's acquisition of Firefly Bio for $1 billion is a strategic move aimed at enhancing their oncology pipeline with Firefly's Degrader Antibody Conjugate platform. This technology is designed to target KRAS-driven tumors, which are notoriously difficult to treat, prevalent in cancers such as pancreatic and colorectal cancer. By integrating Firefly's innovative platform, J&J aims to offer new hope for patients dealing with these challenging cancers. Turning to regulatory developments, the FDA has expanded Pfizer's Hympavzi label to include pediatric patients aged six and older with hemophilia A and B. This decision follows robust Phase 3 results that demonstrate Hympavzi's efficacy as a prophylactic treatment in this young population. The expanded label underscores efforts to address pediatric needs in areas traditionally focused on adults, thus broadening treatment options for young patients with bleeding disorders. In Europe, Chiesi's Loxujta (lomitapide) has gained EU pediatric label expansion for treating homozygous familial hypercholesterolemia, supported by strong Phase 3 data. This expansion aligns with a growing trend toward personalized medicine, tailoring treatments to specific genetic profiles even in younger populations. Collaborative efforts in biotechnology are also gaining momentum. GSK has partnered with Engitix to research liver fibrosis regression through extracellular matrix-targeted drug discovery. This collaboration highlights an industry shift towards leveraging biotechnology for innovative therapeutic solutions. Hikma Pharmaceuticals has shown confidence in the U.S. pharmaceutical manufacturing sector by committing $267 million to expand its facilities in Ohio. This expansion enhances Hikma's production capabilities while creating 350 jobs, positively impacting local economies and ensuring robust supply chain capabilities for essential medicines. The clinical trial landscape is vibrant with promising data across various therapeutic areas. Amgen's Repatha (evolocumab) has demonstrated cardiovascular risk reduction in high-risk diabetes patients without prior heart attacks or strokes, reinforcing its role not just in cholesterol management but also in broader cardiovascular risk mitigation strategies. Dexcom has made strides in metabolic diseases with its G7 continuous glucose monitor showing significant benefits for non-insulin-dependent type 2 diabetes patients. This development illustrates the increasing integration of digital health technologies into chronic disease management. Moreover, emerging treatments like Sciwind Biosciences' ecnoglutide have shown superior weight loss outcomes compared to existing therapies such as semaglutide. Such head-to-head comparisons are crucial for advancing competitive therapeutic landscapes and optimizing patient outcomes. In summary, the pharmaceutical and biotech sectors are experiencing transformative changes driven by scientific advancements and strategic collaborations. These developments not only expand treatment options across various therapeutic areas but also signify a shift toward more personalized and integrated healthcare solutions that could significantly impact patient care and drug development pathways globally. As these trends continue to evolve, they will likely drive further progressions in how pharmaceutical companies approach drug development and regulatory engagements, ultimately benefiting patients worldwide through more effective and personalized treatment modalities. Stay tuned for more updates from Pharma Daily as we continue to bring you the latest insights from the world of pharmaceuticals and biotechnology.Support the show

In this episode, Jack Cochran sits down with Yasmeen Hyder, an enterprise solutions consulting leader from Atlanta, to explore a game-changing approach to working with AI: speaking to it instead of typing. Yasmeen shares how she uses voice-based AI interactions as a thought companion and coaching tool to enhance decision-making, reduce mental load, and work more efficiently in her presales leadership role. Follow Us Connect with Jack Cochran: https://www.linkedin.com/in/jackcochran/  Connect with Yasmeen Hyder: https://www.linkedin.com/in/yasmeenhyder/  Links and Resources Mentioned Join Presales Collective Slack: https://www.presalescollective.com/slack  Sol/Con 2026 (Chicago, August 2026): https://www.presalescollective.com/solcon-2026  Presales Collective Podcast: https://www.presalescollective.com/podcast  Key Topics Covered Voice AI vs. Typing: Why Speaking Creates Higher Bandwidth Communication AI as Thought Companion Rather Than Answer Engine Yasmeen's Career Journey: Healthcare to Pharma to Tech Presales Overcoming the Behavioral Change of Talking to Your Computer Stress Testing Leadership Decisions with Voice AI Using AI as a Coach: Asking for Questions Instead of Answers Time Compression Benefits: 60-90 Minutes Down to 15-20 Minutes Addressing Zoom Fatigue: Voice AI as Reset and Grounding Tool Negative Prompting Technique for Better Outputs Personal and Professional Applications Beyond Work Timestamps 00:00 Introduction 02:45 Welcome Yas 05:45 Why talking to AI 08:02 Setup and behavioral change 10:57 Writing vs. speaking 15:27 Rubber ducky but better 16:28 Stress testing leadership decisions 20:46 Using AI as a coach 22:36 Addressing Zoom fatigue 26:00 Personal life applications 30:19 Closing and contact information  

Regulatory volatility, scientific‑grade context requirements, and entrenched legacy processes are creating a level of operational complexity in pharma that makes even high‑value AI initiatives difficult to move from concept to production. In this episode, Art Shectman, CEO at Elephant Ventures, examines with host Marilie Fouché how leaders can cut through that complexity by isolating a single, clearly defined workflow slice and rebuilding it for near‑term, dependable deployment rather than long‑range architectural perfection. The discussion highlights how removing outdated process assumptions, selecting an atomic workflow with organizational alignment, and aiming for a contained operational win enable pharma teams to build momentum and scale AI responsibly in highly regulated environments. Learn how consultants are winning business with evidence-based AI ROI and building long-term capabilities instead of chasing short-term gains. Download our free PDF report, "3 Keys to Thriving in the Coming Era of Automation," at emerj.com/cok1

Oorlog? Chipbubbel? Inflatie, hogere rentes en rooie borden? Joh, paar nachtjes slapen en je baadt weer in het groen. Welkom in de bullmarkt van 2026. We bespreken alle chiplosers die vrijdag in het rood belandden en vandaag weer vleugeltjes kregen op de beurs. Intel doet een megadeal met Google. Marvell mag misschien wel de S&P 500 in. Broadcom plust omdat het wel genoeg afgestraft was en ook de Nederlandse chipbedrijven wisten weer dikke procenten toe te voegen aan hun waarderingen. Verder moeten we écht praten over die meute gnoes uit de Lion King die in Zuid-Korea over de beurs banjeren. De Kospi-index daalde 8.3 procent vannacht. Honderden miljarden dollars aan rijkdom in een avondje weggevaagd. Arend Jan vertelt hoe hij tóch belegt in die malle bende ten oosten van China en natuurlijk filosoferen we nog even over het einde van de geheugentekorten. Overigens is er één index die het nog veel beter deed dan die landelijke indexen vorig jaar. De Euro Stoxx Bank Index knalde zelfs die dikke 75% van Zuid-Korea makkelijk voorbij in 2025. Daarom barst er nu een nieuwe boardroom battle los in Italië. Kemphanen Banco BPM en Intesa Sanpaolo strijden om de oudste bank ter wereld: Monte dei Paschi di Siena. Zou het dan toch kunnen? Europese bankenconsolidatie, binnen de landsgrenzen? We zullen het zien. Verder in deze aflevering: Hoe Deense afvalprikkenboer Zealand Pharma grote broer Novo Nordisk uitdaagde en... verloor omdat patiënten massaal begonnen te braken Handel in voorkennis, want de AFM waarschuwt firma's die zich bezighouden met fusies en overnames dat er criminelen op pad zijn die koersgevoelige informatie proberen te ontfutselen. Genoeg reden voor Arend Jan om nog eventjes herinneringen op te halen over oude schandalen. Te gast: Arend Jan Kamp van Stockwatch.nl en de podcast Het Beurscafé BNR Beurs is een journalistiek onafhankelijke productie, mede mogelijk gemaakt door Saxo. Over de makers: Jelle Maasbach is presentator van BNR Beurs en freelance financieel journalist. Zijn favoriete aandeel om over te praten is Disney, maar daar lijkt hij de enige in te zijn. Sinds de eerste uitzending van BNR Beurs is 'ie er bij. Maxim van Mil is presentator van BNR Beurs en journalist bij BNR, waar hij zich focust op de financiële markten en ontwikkelingen in de tech-wereld. Je krijgt hem het meest enthousiast als hij kan praten over ASML, of oer-Hollandse bedrijven zoals Ahold of ABN Amro. Jorik Simonides is presentator van BNR Beurs, economieredacteur en verslaggever bij BNR. Hij wordt er vooral blij van als het een keer níet over AI gaat. Je hoort hem ook in de BNR-podcast Moerdijk: dorp van de rekening. Milou Brand is presentator van BNR Beurs, freelance podcastmaker en columnist bij het Financieele Dagblad. Jochem Visser is presentator van BNR Beurs, maakt Beursnerd XL en is redacteur bij de podcast Onder Curatoren. Vraag hem naar obscure zaken op financiële markten en hij vertelt je waarom het eigenlijk nóg leuker is dan je al dacht. Over de podcast: Met BNR Beurs ga je altijd voorbereid de nieuwe beursdag in. We praten je in een kleine 25 minuten bij over alle laatste ontwikkelingen op de handelsvloer. We blijven niet alleen bij de AEX of Wall Street, maar vertellen je ook waar nog meer kansen liggen. En we houden het niet bij de cijfers, maar zoeken ook iedere dag voor je naar duiding van scherpe gasten en experts. Of je nu een ervaren belegger bent of net begint met je eerste stappen op de beurs, de podcast biedt waardevolle inzichten voor je beleggingsstrategie. Door de focus op zowel de korte termijn als de lange termijn, helpt BNR Beurs luisteraars om de ruis van de markt te scheiden van de essentie. Van Musk tot Microsoft en van Ahold tot ASML. Wij vertellen je wat beleggers bezighoudt, wie de markten in beweging zet en wat dat betekent voor jouw beleggingsportefeuille.See omnystudio.com/listener for privacy information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant advancements shaping the landscape of our industry. As technology continues to redefine traditional paradigms, the collaboration between Pfizer and Chai Discovery exemplifies this trend. By harnessing artificial intelligence, particularly through custom models like Chai-3, this partnership aims to revolutionize drug discovery. The integration of AI promises not only to accelerate the identification of biologics and antibodies but also to optimize resource allocation in research and development. Such technological integration could pave the way for an enhanced pipeline of innovative treatments, marking a transformative shift in how therapeutic candidates are developed. In the realm of regulatory developments, Lupin's Ranluspec has recently received FDA approval as an interchangeable biosimilar targeting VEGF-A for various retinal conditions. This move underscores the importance of biosimilars in providing cost-effective alternatives to expensive biologics, thereby expanding patient access to essential treatments for conditions like macular degeneration. Additionally, the MHRA's marketing authorization for Aujemflu, an adjuvanted trivalent influenza vaccine for adults aged 50 and over, reflects ongoing efforts to bolster protection against infectious diseases among vulnerable populations. Clinical trial advancements continue to highlight significant progress in therapeutic development. Otsuka Pharmaceuticals' Phase 3 data on Voyxact has shown promising stabilization of kidney function in patients with Immunoglobulin A nephropathy. This protein therapy targets autoimmune pathways, offering new hope for managing this chronic kidney condition. Similarly, Autobahn Therapeutics' Elunetirom has advanced to a pivotal trial following Phase 2 success in treating bipolar depression. This showcases the potential of small molecule therapies targeting thyroid hormone receptors. Meanwhile, Hikma Pharmaceuticals' victory in a landmark patent case regarding skinny labels marks an important development in pharmaceutical intellectual property rights. The unanimous Supreme Court ruling against Amarin supports the legitimacy of using skinny labels to market generic versions of drugs for non-patented indications. This decision could enhance market competition and drive down healthcare costs, setting a precedent for future intellectual property disputes. On the business front, strategic partnerships and mergers continue to shape industry dynamics. Gilead Sciences' acquisition of Ouro Medicines for $1.675 billion strengthens its autoimmune inflammation pipeline. This transaction exemplifies how major deals are reshaping therapeutic portfolios in response to growing demand for treatments targeting rare diseases. Financially, Solix Pharmaceuticals' success in raising $71 million to advance its siRNA pipeline across multiple therapeutic areas demonstrates investor confidence in RNA-based therapeutics as a promising frontier for innovative treatments. Conversely, challenges persist as evidenced by Takeda's $2.5 billion legal provision over an antitrust case related to Amitiza, underscoring ongoing financial risks associated with litigation in the pharmaceutical sector. Corporate restructuring also signals shifts within the industry landscape. Fulcrum Therapeutics' decision to lay off 85% of its workforce following the discontinuation of its sickle cell disease candidate highlights the volatility and high stakes inherent in drug development. Overall, these developments illustrate a dynamic landscape where scientific innovation is propelled by AI-driven approaches and strategic collaborations while regulatory victories and financial maneuvers shape market dynamics. These trends have profound implications for patient care by potentially accelerating the availability of novel therapies and fostering a competitive environment that drives down costs. As we look ahead, stakeholders must navigate these complexities effectively to harness opportunities and address challenges within this rapidly evolving industry landscape. The ability to adapt and capitalize on emerging trends will be crucial as these sectors continue to evolve, ultimately enhancing patient care and advancing therapeutic frontiers globally. Thank you for joining us today on Pharma Daily; stay tuned for more insights into the ever-changing world of pharmaceuticals and biotech.Support the show

The Nurses Report with Ashley, Nicole, & David – FDA leadership shifts as Kyle Diamantas steps into power, raising alarms over his past work defending pharmaceutical companies in Abilify litigation. The story connects Mirapex, hidden safety signals, sealed settlements, and regulatory failure, arguing that drug victims face impossible burdens while pharma profits from secrecy, influence, and institutional protection today...

The Nurses Report with Ashley, Nicole, & David – FDA leadership shifts as Kyle Diamantas steps into power, raising alarms over his past work defending pharmaceutical companies in Abilify litigation. The story connects Mirapex, hidden safety signals, sealed settlements, and regulatory failure, arguing that drug victims face impossible burdens while pharma profits from secrecy, influence, and institutional protection today...

Arun Krishnan, SVP of Global Supply Chain and Strategy at AstraZeneca, shares how the company is reimagining its supply chain to support ambitious growth while keeping patients at the center. He discusses AstraZeneca's focus on innovation, AI-enabled ways of working, self-healing supply chains, and the importance of building capabilities for the future. Arun also explains how the organization continues to maintain strong global supply delivery amid volatility, from the pandemic to geopolitical disruption. Throughout the conversation, he emphasizes the role of curiosity, continuous learning, and empowered leadership in helping people and supply chains adapt to a rapidly changing world.Discover more details here.Follow us on:Instagram: http://bit.ly/2Wba8v7LinkedIn: https://bit.ly/4hbidqoFacebook: http://bit.ly/2HtryLd

Vor allem durch die Pläne von Gesundheitsministerin Nina Warken gerät die Bundesregierung unter Druck der Wirtschaft – wie zwei aktuelle Fälle mit drastischen Folgen diese Woche zeigen.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the evolving landscape of the pharmaceutical and biotechnology industries, where scientific advancements, regulatory updates, and strategic business decisions are reshaping the future. A significant development in this dynamic arena is the strategic withdrawal by Eli Lilly and Boehringer Ingelheim from planned investments in Germany. Both companies have decided to cut at least $1 billion each from their investments, a direct response to Germany's healthcare reforms targeting reduced branded drug prices. This decision highlights how governmental policy can significantly influence pharmaceutical investment strategies, prompting companies to be more cautious in markets with strict pricing controls. Another critical area of focus is clinical trials, where ADC Therapeutics has encountered a significant challenge. The company's antibody-drug conjugate, Zynlonta, which was granted accelerated FDA approval in 2021, recently reported three times as many deaths in its study arm compared to the control group. This raises important questions about the safety profile of antibody-drug conjugates, a class of drugs celebrated for their potential in targeted cancer therapy. The situation underscores the ongoing struggle to balance efficacy with safety in innovative cancer treatments. Regulatory oversight remains a pivotal aspect of the industry. The FDA recently issued a warning letter to Medline over recurring issues with toxic bacteria in finished products, emphasizing the critical need for compliance and safety within the medical device sector. Additionally, an untitled letter was sent to QOL Medical for potentially misleading promotional communications regarding Sucraid. Such actions demonstrate the FDA's vigilance in monitoring marketing practices that could mislead healthcare providers or patients. In drug approval news, AbbVie's Qulipta and Amgen's Imdelltra have secured approvals in Europe. These milestones are part of a broader strategy by pharmaceutical companies to expand geographically and enhance product portfolios through new indications. Meanwhile, Axsome Therapeutics successfully defended its narcolepsy medication Sunosi against generic competition until 2040 by settling patent litigation with a prospective generic manufacturer. This move reflects the intense patent battles common in the industry to extend product lifecycles and maintain market exclusivity. Turning to geopolitical influences, there is heightened scrutiny on China's biotech sector following calls from U.S. lawmakers for increased oversight. The potential application of the Comprehensive Outbound Investment National Security Act to Chinese biotech investments signals escalating tensions and could significantly impact international collaborations and investments. This reflects growing concerns over intellectual property protection and biotechnological advancements within international trade dynamics. In financial developments, Parabilis Medicines is preparing for an IPO with aims to raise $476 million to fund Phase 3 trials of its desmoid tumor drug candidate. This move illustrates continued investor interest in oncology innovations despite broader economic uncertainties. On the scientific front, Autobahn Therapeutics is making strides with its thyroid hormone receptor stimulator, showing efficacy in reducing depression symptoms in bipolar disorder during Phase 2 trials. This success paves the way for pivotal trials and highlights how hormone mimics can offer new therapeutic avenues for neuropsychiatric disorders. Meanwhile, Alnylam Pharmaceuticals has entered into a groundbreaking $2 billion agreement with Inceptive Nucleics to incorporate artificial intelligence into small interfering RNA design. By leveraging AI-driven methodologies, Alnylam aims to enhance precision and efficacy in siRNA therapies, potentially speeding up drug discovery processes. Operational challenges are also evident as companies navigate complex markets like Japan, underscoring the importance of integrating regulatory and strategic planning early on to mitigate risks and ensure market feasibility. These developments paint a vivid picture of a vibrant pharmaceutical and biotech landscape where scientific innovation is rapidly advancing alongside strategic partnerships and regulatory oversight. Breakthrough technologies such as AI-driven drug design hold promise for more targeted therapies while emphasizing personalized medicine approaches. However, these advancements come with challenges like safety concerns and regulatory compliance that demand constant vigilance and adaptability from industry stakeholders. The implications for patient care are significant as these scientific breakthroughs promise new treatment avenues for complex diseases while highlighting personalized medicine approaches. As these industries continue to evolve, staying informed about scientific innovations and regulatory landscapes will be crucial for stakeholders aiming to drive future growth and improve global health outcomes. Thank you for tuning into Pharma Daily. Stay informed and stay ahead with us as we continue to bring you the latest insights from around the pharmaceutical and biotech world.Support the show

All new website and player at: https://jviz.net Support: https://jviz.net/donate Merch: https://jviz.net/merch Tracklist: https://serato.com/playlists/JVIZ/2026-06-04 Full track list below: Dubmentalist – Passengers Leo Cap – Hate XI, Somebodyyyy, Doni Rampage – Turn Up 4CROWNS, Sparkz – Roller R3ST – Nautilus Nika D, Abstrakt Sonance – Elevation (Explicit) OldGold – Displace The Sound Kercha – Hard Choice Yoofee – Fermata Acid – Brut HIJINX, Vitamin G – Don’t Ask Why Darkai – Low Tek Dusty – Grutbucker (Nova Remix) ColtCuts & CØNTRA – Lockup Disrupta, Latte, B Live – OMG (Distinct Motive Remix) Dr. Ushūu – Let Me RÜGER – Silk & Cinders HIFEELINGS – Take U There Wraz., Motus – Demons Nautical Divine – Platinum Azotix – Ego Kercha – This Is My Rap Kercha – Mind Extraction Skream – The Soul Platypus – GRMP (M.A.W. remix) Pharma – Shift (Causa Remix)

In today's episode on 4th June 2026, we talk about India's first homegrown drug and why it took Indian pharma so long to get here.Book a FREE call with Ditto

Isaac Conyers IV, Director of Operations at Marco Pharma International, a family-owned distributor of German biological medicines joins Enterprise Radio. Listen to interview with … Read more The post How Marco Pharma International Turned Principle Into a 35-Year Business Strategy appeared first on Top Entrepreneurs Podcast | Enterprise Podcast Network.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the most significant advancements in scientific research, clinical trials, and regulatory landscapes within the industry. These developments are shaping the future of patient care and drug development significantly. Starting with Legend Biotech's LB2501, which achieved an impressive 100% response rate in a Phase 1 study for non-Hodgkin lymphoma using in vivo CAR T-cell therapy. This breakthrough highlights the transformative potential of CAR T-cell therapies in oncology, especially for B-cell lymphomas. Such success opens the door for accelerated regulatory pathways, offering hope to patients with limited treatment options. In another key development, JJP Biologics shared positive interim data from its Phase 1b trial of nebaprubart targeting CD89 in linear IgA disease. This monoclonal antibody is promising in treating autoimmune conditions by targeting specific disease mechanisms. Meanwhile, GSK's Velzatinib (IDRX-42) achieved a 61% response rate in Phase 1/1b trials for gastrointestinal stromal tumors, showing efficacy against cases resistant to treatments like imatinib. Johnson & Johnson's Nipocalimab met its primary endpoint in a Phase 2 study for systemic lupus erythematosus, underscoring the potential of FcRn blockade in managing autoimmune diseases. Zenas Biopharma's Phase 3 data for Obexelimab targeting CD19/FcγRIIB in IgG4-related disease further emphasizes the role of targeted therapies in managing complex autoimmune disorders. On the regulatory front, Foundation Medicine's FoundationOne Blood Test received FDA approval as a companion diagnostic for Pfizer's Talzenna (talazoparib) to treat prostate cancer with homologous recombination repair gene mutations. This approval underscores the growing importance of precision medicine and companion diagnostics in tailoring cancer treatments based on genetic profiles. Additionally, Lupin and Natco Pharma secured FDA approval for their generic version of Eribulin Mesylate Injection, essential for reducing healthcare costs and improving patient access to vital therapies. Eli Lilly's collaboration with Ascidian Therapeutics focuses on RNA exon editing for kidney diseases, potentially revolutionizing treatment approaches by correcting genetic errors at the RNA level. This partnership reflects a burgeoning interest in RNA-based therapies and their capacity to address unmet medical needs. Regeneron expanded its pact with CytomX Therapeutics to develop conditionally active bispecific antibodies, emphasizing innovation in oncology drug discovery. Such collaborations combine expertise across companies to expedite cutting-edge therapies' development. In terms of funding, NewLimit's successful $435 million Series C round aims to advance epigenetic reprogramming medicine towards human trials. This initiative highlights the burgeoning field of aging biology and its implications for extending healthy human lifespan through innovative therapeutic approaches. Similarly, Immu Biosciences raised $53 million to enhance its immunology platform using AI/ML technologies, underscoring AI and machine learning's critical role in accelerating drug development processes. Turning our gaze towards China's expanding influence on the global biotech stage, Akeso's presentation at ASCO 2026 marked a significant milestone as it became the first-ever Chinese dataset featured in a plenary session. This achievement underscores China's growing prominence in biotechnology and highlights its commitment to advancing innovative medical solutions globally. Simultaneously, Gilead's strategic partnership with Cencora aims to enhance access to CAR-T therapies like Yescarta and Tecartus by expanding their network of treatment centers. CAR-T therapies represent a paradigm shift in cancer treatment by offering personalized options for certain types of cancer. Despite challenges such as Roche's setbacks with its oral SERD drug giredestrant in breast cancer trials, innovation continues unabated. Zevra Therapeutics' launch of Miplyffa for Niemann-Pick disease type C exemplifies efforts to transform rare disease markets by improving patient outcomes through increased access and tailored treatment strategies. Finally, Eli Lilly's acquisition spree reflects broader trends where pharmaceutical companies increasingly integrate Chinese innovations into their development pipelines. This period marks a transformative phase characterized by collaboration between global pharma giants and Chinese biotechs, signaling an era where innovation is globalized and aimed at addressing critical healthcare challenges worldwide. These advancements reflect a dynamic period of innovation within the pharmaceutical and biotech industries. The focus on personalized medicine, targeted therapies, and groundbreaking technologies like RNA editing indicates a shift towards more precise treatment modalities. As these discoveries transition from research phases to clinical applications, they hold the potential to transform patient care significantly. Strategic partnerships and substantial funding initiatives illustrate a robust ecosystem supporting these innovations' rapid advancement. As regulatory bodies continue approving novel therapeutics and diagnostics, the emphasis on personalized healthcare will likely drive future developments, ultimately leading to improved patient outcomes worldwide. As we continue navigating these developments, it's clear that the pharmaceutical and biotech sectors are on the cusp of transformative breakthroughs that promise to redefine healthcare delivery across multiple domains. Thank you for tuning into Pharma Daily; stay informed and stay ahead.Support the show

Running a business in Ireland is expensive. Energy bills are one of the biggest overheads for businesses across the country, and the building you operate from has more impact on those bills than most business owners realise. New research from Procure.ie analysed at 80,526 non-domestic building energy ratings (BER) published by the Central Statistics Office (CSO), which measures the energy performance of commercial and public buildings such as offices and warehouses across Ireland between 2009 and 2025, to find out which counties are leading the way. Counties were then ranked by how many of their buildings achieved an A rating, the highest score a building can get. Kildare came out on top by a landslide, with 7% of its buildings (235 out of 3,355) rated A. That's almost double the national average of 3.6%. The county has become a hub for modern, energy-efficient commercial development, with planners recently approving a €3 billion data-centre campus by Herbata at Naas, and Kildare's pharma and semiconductor sites being built to high standards. Three counties share second place, each with 5% of their commercial buildings A-rated. County Dublin leads the trio with 296 out of 5,915 buildings achieving an A rating. Meath follows with 134 out of 2,672 buildings A-rated. The new 21,000 sq ft Thrive Centre of Business Excellence opened in September 2025, offering dedicated climate action services and adding to the county's growing reputation for energy-smart business. Westmeath completes the joint second-place trio, also at 5% (84 out of 1,684 buildings). In September 2025, Westmeath County Council signed contracts to upgrade its three biggest buildings (Áras an Chontae in Mullingar, the Civic Centre in Athlone, and Athlone Regional Sports Centre) to high energy-efficiency standards. Ballymore Group has also announced plans for a new sustainable town in Athlone, designed for 100,000 residents by 2040, with 90% of its energy coming from renewables. Longford (4.1%) and Laois (4%) rank in third and fourth place respectively, showing that even smaller counties can make a massive impact. Longford County Council received €793,822 from the EU Just Transition Fund to develop the Longford Enterprise and Energy Centre, and Laois County Council recently signed a multi-million-euro funding agreement with the Sustainable Energy Authority of Ireland (SEAI) to retrofit buildings across the Midlands. The Rebel County rounds out the top five, with 291 out of 7,263 commercial buildings achieving an A rating. Cork has more commercial buildings in this dataset than any county outside Dublin, and it is one of Ireland's biggest business counties for a reason. Pharma, tech, and manufacturing companies have all planted roots there. At the other end of the list, Limerick City has the highest proportion of G-rated commercial buildings in the country at 17%, making it the worst-performing county in Ireland. Kilkenny and Sligo are not far behind at 16%, with Louth and Monaghan following at 14%. A lot of this comes down to older heritage buildings and ageing warehouses along the Dublin-Belfast route. For more information and to view the full research, please visit: https://www.procure.ie/irelands-most-energy-efficient-counties/ Procure.ie analysed 80,526 non-domestic BER audits by county, published by the Central Statistics Office (CSO), covering everything from offices and warehouses to hotels, schools, hospitals and shops across Ireland between 2009 and 2025, to find out which counties are the most energy efficient. About Procure.ie Procure.ie are Ireland's largest business utility consultants, specialising in providing strategic guidance and solutions to businesses across the country. Procure.ie offers comprehensive services ensuring you get the best deal across energy and merchant services. See more breaking stories here. Irish Tech News are Ireland's No. 1 Online Tech Publication and often Ireland's No.1 Tech Podcast too. You can find hundreds of fantasti...

Dr. Tom Elliott has spent more than four decades at the forefront of diabetes, endocrinology, and metabolic health.He is the founder and medical director of BC Diabetes, an associate professor at UBC, and has been involved in more than 20 pharmaceutical clinical trials exploring the future of obesity, diabetes, and GLP-1 therapies. In this episode, Dr. Elliott breaks down why obesity, insulin resistance, and prediabetes have exploded across modern society, and why many founders and high performers are quietly damaging their metabolic health through stress, poor sleep, alcohol, sedentary work, and overstimulation.We explore the science behind Ozempic, GLP-1 agonists, retatrutide, testosterone decline, fertility, fasting, aging, addiction, and the future of preventative medicine. Dr. Elliott also explains why some patients in clinical trials “begged to stop” after losing too much weight, and how these drugs may extend far beyond weight loss into addiction recovery and longevity research.You will learn:Why more than 150 million Americans may be prediabeticWhat GLP-1 drugs actually do inside the bodyWhy Ozempic is affecting fertility, appetite, and addictionHow stress and sleep deprivation damage metabolismWhy muscle mass and strength matter as you ageThe relationship between testosterone, aging, and performanceHow modern food environments accelerate obesity and insulin resistanceThis is a wide-ranging conversation on diabetes, longevity, performance, and the future of human health with one of Canada's leading endocrinologists.

Sitting on the fence feels like the smart move. You weigh the pros and cons, you do the research, you tell yourself now isn't the right time. But indecision is still a decision, and in a pharma career it has a cost. The promotion you're not sure you're ready for. The role you can't decide is right. The difficult stakeholder you don't know how to handle. Every time you stay on the fence to avoid the discomfort of the unknown, you make less progress and you quietly hand the opportunity to someone who decided faster. This episode is about why we do it, and how to get down.In this episode, you'll learn:What sitting on the fence really meansThe questions that expose the real reason you're not making a decisionHow to calculate the actual cost of indecision before it costs you in your careerWhere certainty about a decision actually comes fromGet the Book: Your Worthy Career: A Science-Backed Method to Build a Meaningful Career in Pharma and Biotech here.Work with Me: Learn more and apply to work with me here.Love the podcast?  Share your feedback by leaving us a review. Thank you!Connect on SocialsLinkedInInstagram

Plus: a pill that could double survival time for patients with pancreatic cancer could soon be coming to Canada, Zellers is continuing to accelerate its comeback in Canada, the latest on CBS's firing of veteran news correspondent Scott Pelley, and how can provincial Liberals make a comeback? We love feedback at The Big Story, as well as suggestions for future episodes. You can find us: Through email at hello@thebigstorypodcast.ca  Or @thebigstory.bsky.social on Bluesky

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into a series of groundbreaking advancements and strategic maneuvers reshaping the landscape of drug development and patient care. In recent news, Moderna and Merck & Co. have reported substantial progress in cancer treatment with their Phase 2b trial results involving Intismeran Autogene combined with Keytruda. This combination therapy, leveraging the innovative mRNA vaccine technology alongside Keytruda, has shown a remarkable 49% reduction in recurrence risk for high-risk melanoma patients. This synergy not only enhances therapeutic options in melanoma but also underscores the transformative potential of mRNA vaccines beyond infectious diseases, suggesting a new frontier for oncology treatments. Bristol Myers Squibb has also made significant strides with its Phase 3 trial results for Izalontamab Brengitecan, an antibody-drug conjugate. This therapy has demonstrated a 40% reduction in death risk among patients with triple-negative breast cancer—an aggressive subtype with historically limited treatment options. The success of this bispecific antibody targeting Trop2 highlights the advancing trend towards precision medicine, where therapies are increasingly tailored to specific genetic and molecular profiles, promising improved patient outcomes. Turning to business developments, Rallybio's merger with Avenzo Therapeutics through a reverse merger transaction marks a notable consolidation trend within the industry. Supported by a $215 million private placement, this merger aims to accelerate drug discovery and development in oncology, emphasizing the importance of strategic collaborations in enhancing therapeutic pipelines. Similarly, MindMaze Therapeutics is streamlining operations post-merger by refocusing on core competencies aligned with broader industry trends towards specialization. Regulatory updates have been equally dynamic. Shionogi's Xocova (Ensitrelvir) has received FDA approval for post-exposure prophylaxis against COVID-19 following successful Phase 3 trials. As a small-molecule protease inhibitor, Xocova enriches the therapeutic arsenal against COVID-19 and reflects ongoing efforts to manage infectious diseases even as the pandemic wanes. Strategic partnerships are further shaping the industry landscape. The collaboration between ASCO and Ryght AI aims to enhance breast cancer trial site selection using artificial intelligence. This initiative signifies a growing trend towards integrating AI and machine learning technologies in clinical trial optimization to streamline processes and improve efficiency—an essential endeavor as trials become more complex and data-driven. Additionally, Sanofi's integration of AI via field agents to enhance efficiencies across business facets highlights how AI adoption is accelerating and promises to reshape drug development processes and patient care strategies significantly. Meanwhile, challenges persist. The FDA's rejection of Cingulate's CTX-1301 due to manufacturing concerns underscores the rigorous regulatory environment that companies navigate. Similarly, Roche's Persevera trial missing its primary endpoint in breast cancer treatment highlights the inherent risks involved in drug development. In scientific advancements, Gilead Sciences has made progress with Livdelzi in treating primary biliary cholangitis (PBC), a rare liver disease. The Phase 3 trial success points to ongoing innovation in rare disease treatments—a critical area for enhancing patient outcomes. On another front, Contraline is advancing its male birth control candidate after securing $92.5 million in funding. This first-in-class topical contraceptive fills a significant gap in male contraceptive options, demonstrating an increasing focus on diversifying reproductive health solutions. In strategic shifts within the industry, Merck is reducing its workforce as part of a broader $3 billion cost-cutting strategy aimed at optimizing operations while investing in innovation and technology. At ASCO 2026, Celcuity shared ambitions to revolutionize breast cancer treatment paradigms through innovative pathway targeting, while GSK introduced a new approach for rare gut cancers—conditions that have seen little advancement over decades. Such initiatives highlight critical roles innovative research plays in oncology. In summary, these developments reflect a vibrant period for the pharmaceutical and biotech sectors characterized by scientific innovation, strategic mergers, regulatory milestones, and ongoing clinical trials that collectively promise to enhance patient care. Emphasis on personalized medicine, expansion of mRNA technology into oncology, and AI-driven efficiencies are poised to redefine approaches across therapeutic domains while navigating stringent regulatory standards and market dynamics that require strategic agility and robust R&D pipelines. Thank you for tuning into Pharma Daily—your source for insightful updates from the world of pharmaceuticals and biotechnology. Stay connected for more groundbreaking news and analysis shaping the future of healthcare.Support the show

In the late 1980s, a child exposed to fallout from the Chernobyl disaster lay in a hospital bed while doctors told his family there were no clear answers and no reliable path forward. Decades later, that same child, Yan Leyfman, walks into exam rooms as a hematology oncology fellow, expected to deliver clarity inside a system that still runs on delay, uncertainty, and institutional self preservation.This episode traces the throughline from early life shaped by radiation exposure and hospice level uncertainty to a career inside academic medicine, translational research, and oncology media. Yan built his identity around survival and usefulness, moving from patient to physician while carrying the memory of what it feels like to sit on the other side of the table. He helped launch MedNews Week during the COVID crisis to push back on misinformation and expand access to medical knowledge, stepping into a public role while still in training.The conversation stays grounded in the friction between personal narrative and system reality. Clinical training demands efficiency, hierarchy, and emotional distance. Cancer care demands time, clarity, and human connection. Those forces collide in real patient encounters where prior authorization delays, insurance barriers, and fragmented care pathways shape outcomes as much as any treatment protocol.Yan speaks openly about mentorship, belonging, and the drive to make meaning out of survival. The discussion pushes further into what the healthcare system actually rewards, what it quietly strips away, and how quickly empathy can erode under institutional pressure. The episode also examines the role of medical media, where education, industry influence, and narrative control often blur together.This is a conversation about identity under construction, about what happens when someone who remembers powerlessness steps into a role that carries authority, and about whether that memory can survive long enough to change anything.RELATED LINKSYan Leyfman on LinkedInYan Leyfman on InstagramSurviving ChernobylFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Most pharma launch frameworks don't fail because they lack structure; they fail because they become rigid checklists that kill strategic thinking. In this episode, Lumanity's Business Development Director, Jeff Hart, and Launch Excellence Principal, Kirsty Tait, talk about how pharmaceutical companies can scale launch excellence as pipelines grow and complexity increases. Kirsty and Jeff explain that rigid, one-size-fits-all frameworks lead to inefficiency, slow decisions, and misalignment across global and local teams. Instead, organizations need a standardized operating system with built-in flexibility to tailor strategy by asset and market. Ultimately, success depends not just on process, but on strong governance, a single source of truth, and a winning culture that drives execution. If your launch process feels slow, inconsistent, or overly complex, this conversation will help you rethink how to scale without losing speed or impact. Resources: Follow Lumanity on LinkedIn and explore their website! Connect with and follow Kirsty Tait on LinkedIn. Connect with and follow Jeff Hart on LinkedIn. Take a look at the Launch Excellence Health Check here! Learn more about this series we're doing with Lumanity here: https://lumanity.com/commercialization-podcasts

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a range of fascinating advancements in the industry, each with significant implications for future patient care and drug development. At the recent American Society of Clinical Oncology (ASCO) 2026 conference, Akeso's ivonescimab, a pioneering PD-1xVEGF bispecific antibody, demonstrated a 34% reduction in death risk when combined with chemotherapy for first-line lung cancer treatment. This marks a pivotal moment in cancer therapeutics, illustrating how bispecific antibodies can enhance treatment efficacy. The evolving landscape of cancer treatment continues to highlight the importance of these innovative approaches. Johnson & Johnson's Erleada has shown promising results in prostate cancer, achieving positive outcomes in its Phase 3 Proteus study. The trial emphasized the efficacy of Erleada when administered perioperatively to prostate cancer patients, indicating a shift towards more personalized and comprehensive care that incorporates targeted therapies before and after surgery. In another significant breakthrough, Lilly's Retemvo exhibited dramatic results in early-stage lung cancer with RET fusion-positive markers, reducing disease progression or death by 83% as adjuvant therapy. This underscores the critical role of molecularly targeted therapies for patients with specific genetic profiles, offering hope for improved survival outcomes. On the frontlines of infectious diseases, Shionogi's COVID-19 antiviral Xocova has received FDA approval as a post-exposure prophylactic. This milestone highlights the challenging yet dynamic landscape of antiviral drug development, offering a new tool in managing COVID-19 exposures after previous challenges in demonstrating effectiveness as a treatment. MannKind's inhaled insulin, Afrezza, has been approved for pediatric use. This approval could rejuvenate its market presence by providing a more convenient insulin delivery system aimed at improving adherence and glycemic control among younger patients. In oncology news, Pfizer's Talzenna combination therapy received broader FDA approval for castration-sensitive prostate cancer. This positions it as a competitive option against Johnson & Johnson's PARP inhibitor combination therapy. Additionally, AstraZeneca's Imfinzi and Imjudo combination showed promise in early-stage liver cancer by reducing disease progression risks by 30%, broadening immunotherapy applications. The market dynamics are also shifting with significant strategic movements like Eli Lilly's acquisition of Kelonia Therapeutics for $3.2 billion. This decision is driven by promising in vivo CAR-T data demonstrating unprecedented response rates and reflects the increasing importance of innovative CAR-T therapies in oncology. Eli Lilly's Kelonia Therapeutics' cell therapy showcased an impressive 100% response rate in a Phase 1 trial for relapsed or refractory multiple myeloma. This CAR-T therapy targets the BCMA antigen and could revolutionize treatment paradigms by offering more effective responses. Meanwhile, Pfizer's transformative research on RAS inhibitors holds potential to redefine treatment paradigms in pancreatic cancer—a notoriously difficult-to-treat type due to its complex biology. Revolution Medicines aims to maintain its leadership within this space amidst growing competition. Revolution Medicines also reported compelling results with their KRAS inhibitor, which nearly doubles survival rates for metastatic pancreatic cancer patients harboring KRAS mutations. Given the historically poor prognosis associated with pancreatic cancer, these findings represent a significant advancement in managing this aggressive type. In ovarian cancer research, Gilead's TUB-040 demonstrated a 61% tumor response rate for platinum-resistant ovarian cancer in a Phase 1 trial. This highlights the potential of antibody-drug conjugates (ADCs) to overcome resistance mechanisms and improve outcomes in difficult-to-treat cancers. Regulatory updates include Johnson & Johnson receiving FDA label expansion for Tremfya to inhibit structural joint damage in active psoriatic arthritis patients. This expansion provides broader treatment options for patients suffering from debilitating conditions by reinforcing the role of IL-23 inhibitors in autoimmune disease management. Strategic partnerships are also shaping drug development's future landscape. Notably, Servier's acquisition of Edgewise Therapeutics' muscular dystrophy unit underscores growing focus on rare diseases and neuromuscular disorders. Eli Lilly's agreements with Haisco Pharmaceutical and Hanmi Pharm reflect ongoing R&D investments aimed at expanding therapeutic portfolios across various indications. These developments illustrate a broader trend toward personalized medicine and targeted therapies that enhance treatment efficacy by leveraging specific genetic or molecular characteristics. Despite advancements, challenges remain as exemplified by Oculis' OCS-01 failing Phase 3 trials for diabetic macular edema—highlighting inherent risks in drug development. Overall, these updates underscore significant scientific progress and promise improvements in patient outcomes through novel therapeutic approaches and collaborative efforts within this vibrant industry landscape.Support the show

In Part 2 of this conversation, Dr. Sina McCullough returns to unpack what may be one of the most overlooked—and unsettling—developments in our food system.   She introduces the concept of "pharma crops"—foods like corn, rice, and lettuce that are being genetically engineered to produce pharmaceutical compounds, including vaccines. While this technology has been in development for decades, Sina explains why its potential entry into the food supply raises serious questions about safety, transparency, and control.   We also explore the gaps in regulation—how these crops are tested (or not), what happens when contamination occurs, and why consumers are often left in the dark. Sina walks us through the "GRAS" loophole—"generally recognized as safe"—and how thousands of chemicals have entered our food supply without meaningful oversight.   From there, we take a closer look at what's actually in our food today… why labels like "gluten-free" can be misleading… and how processed foods dominate the modern diet.   Finally, Sina brings it back to the individual—offering a grounded and empowering perspective on how to navigate all of this without fear. She shares simple but powerful steps for becoming a more informed consumer and reconnecting with your body's own wisdom. This episode is both eye-opening and empowering—a call to look more closely at what we eat, how it's produced, and the choices we make every day. WAPF Ad- WAPF is active on IG, FB, MeWe & Telegram - Join us! Visit Dr. Sina McCullough's website to learn more Join the Nourishing Our Children closed Facebook group Check out our sponsors:  Nutrition Therapy Institute "WAPF listeners get 50% off their first course " and  Goddess Vitality From Optimal Carnivore - "Discount code WESTON10 for 10% off."

This is a corporate-focused, conversational interview between Pharmacy Podcast Network Host, Todd Eury and Stephen Beckman, CEO of YARAL Pharma. The discussion explores YARAL Pharma's unique approach to the U.S. generics market, its commitment to innovation and accessibility, and the company's philosophy of “Doing Things Differently” by redefining what it means to be a generics partner. Stephen Beckman also shares insights into YARAL's growth and key milestones since launching its first product in 2023, including the expansion of its product portfolio, investment in business development, and focus on building a strong company culture.

What happens when a successful oncologist leaves clinical practice to help develop cancer treatments on a global scale? In this episode of The Lebanese Physicians Podcast, Dr. Safi Shahda shares his journey from academic oncology to leadership roles at Eli Lilly, Intellia Therapeutics, and AstraZeneca. We discuss career transitions, pharma misconceptions, innovation, AI in drug development, mentorship, and how physicians can expand their impact beyond the bedside. #LebanesePhysiciansPodcast #PharmaCareers #Oncology #ClinicalResearch #DrugDevelopment #MedicalLeadership #PhysicianCareer #AstraZeneca #Biotech #HealthcareInnovation #ArtificialIntelligence #CancerResearch #MedicalEducation #CareerGrowth #PhysicianLife #Medicine #Subscribe #Podcast #Healthcare #clinicaltrials ⁨@thelebanesephysicianspodcast⁩   ⁨@astrazeneca⁩  On all podcast apps Website: https://thelebanesephysicianspodcast.podbean.com

Matthew Zachary is a brain cancer survivor, healthcare advocate, founder of Stupid Cancer and We the Patients, and host of Out of Patients. In April 2026, he returned to the stage at Merkin Hall near Lincoln Center for his first solo public piano concert in almost 22 years while launching his debut book, We the Patients: Understanding, Navigating, and Surviving America's Healthcare Nightmare.What unfolded became far larger than a concert.Over 2 hours, survivors, clinicians, advocates, nonprofit founders, journalists, pharmaceutical sponsors, and healthcare insiders gathered in one room to reflect on 30 years of survivorship, institutional failure, accidental advocacy, and the emotional afterlife of cancer. The evening moved through original piano performances, live chapter readings, and deeply personal conversations about infertility, disability, financial toxicity, insurance denials, grief, burnout, and what happens when patients spend decades navigating systems designed around transactions instead of continuity.Guests including Wendell Potter, Maimah Karmo, Craig Lustig, Shelly Fuld Nasso, Tamika Felder, and others reflected on how the modern cancer advocacy movement emerged largely because patients built parallel systems where healthcare infrastructure failed to meet human needs. The conversation explored how prior authorization, reimbursement incentives, administrative fragmentation, and institutional distrust continue shaping the patient experience across oncology and survivorship.The performance also marked a deeply personal milestone. After brain cancer compromised his left hand at age 21, Zachary spent 6 months rehabilitating both hands to return to public performance for the first time in over 2 decades. The result became part concert, part civic gathering, and part historical record of a generation of survivors who refused to disappear quietly.RELATED LINKSMZLIVE Official WebsiteMZLIVE YouTube VideoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

There's SO much information about wellness hacks, it's hard to know what's worth trying. And then there are pharmaceuticals like GLP-1 medications that seem like the magic bullet for metabolic health. With all of these, are we setting ourselves up for the next public health crisis? Before you or someone you love considers a pharmaceutical or biohack, listen to this episode. Jenn Trepeck of Salad with a Side of Fries breaks down why the wellness industry deserves more credit than mainstream media gives it, and why pharmaceutical solutions like GLP-1 medications and statins cannot carry the full weight of America's health crisis. From affordable, healthy eating strategies to the alarming long-term risks of overreliance on a single hormone pathway, Jenn makes a compelling, research-backed case for a more comprehensive approach to metabolic health. What You Will Learn in This Episode:✅ Why GLP-1 medications may be following the same trajectory as statin drugs, and what that historical pattern reveals about where we are headed with metabolic health and long-term outcomes.✅ How eating in season and shopping at ethnic grocery stores can make whole foods nutrition genuinely affordable, healthy eating for more people, regardless of income level.✅ The critical connection between reduced food intake on GLP-1 medications, nutrient deficiency, and the alarming rise of osteoporosis and cancer risk, especially for younger populations and children.✅ Why fat cell memory and the Minnesota Starvation Experiment both reveal that weight loss without lifestyle medicine and nutritional education is unlikely to produce lasting results.The Salad With a Side of Fries podcast, hosted by Jenn Trepeck, explores real-life wellness and weight-loss topics, debunking myths, misinformation, and flawed science surrounding nutrition and the food industry. Let's dive into real-life wellness and weight loss, including drinking, eating out, and skipping the grocery store.TIMESTAMPS: 00:00 Why mainstream media voices unfairly dismiss the wellness industry05:50 A critique of how major journalists cover GLP-1 medications without consulting balanced sources or opposing viewpoints13:33 The argument that pharmaceutical solutions have become the default answer instead of addressing the root causes of metabolic health issues22:29 Discussion of income, access, and why processed foods are cheaper than whole foods nutrition is a structural public health failure30:37 Practical tips for affordable healthy eating, including seasonal eating and shopping at ethnic grocery stores for better quality produce34:39 The GLP-1 conversation begins in earnest, with Jenn explaining why she calls them our generation's statin drug37:02 A deep dive into statin drug statistics, heart disease rates, and why more prescriptions have not produced better cardiovascular health outcomes41:14 Jenn outlines her predictions, including rising osteoporosis risk, bone density loss, and increased colorectal cancer risk tied to low fiber intake44:31 The role of fat cell memory, the Minnesota Starvation Experiment, and why GLP-1 medications without lifestyle medicine will not produce lasting changeKEY TAKEAWAYS:

In December 1996, a 37 year old pharmaceutical executive sat in a Borders bookstore reading medical textbooks on the floor, trying to understand a disease she had never heard of. Multiple myeloma carried a three year prognosis. Her daughter was 18 months old. Her father had just died of cancer. Within weeks, she pushed her doctors to say the quiet part clearly. This would likely end her life before her child entered kindergarten.Kathy Giusti refused to accept passive survival. She built a plan while the system offered fragments. She interviewed oncologists and fertility specialists at the same time. She pursued IVF to have a second child while preparing for treatment. She stayed employed to keep insurance coverage. Every decision carried financial, medical, and emotional risk.That same urgency exposed a deeper failure. Cancer research moved slowly. Academic centers guarded data. Clinical trials lacked coordination. Patients entered a system that demanded compliance without providing clarity. Giusti responded by building the Multiple Myeloma Research Foundation, not as a support group, but as an operating engine to accelerate drug development, fund research, and force collaboration across institutions.This episode tracks the tension between individual agency and systemic failure. Giusti describes how patients navigate diagnosis, insurance barriers, and fragmented care in real time. She explains how data, genomics, and clinical trials reshape cancer treatment while still leaving patients responsible for decisions they are not trained to make. She addresses disparities in access, the limits of early detection, and the reality that progress in oncology often depends on speed, funding, and alignment of incentives.The conversation moves between lived experience and structural critique. It names the cost of delay, the burden placed on patients to act as their own advocate, and the tradeoffs required to push a system forward that still protects itself first.⸻RELATED LINKSKathy GiustiMultiple Myeloma Research FoundationFatal to FearlessAmerican Society of Hematology⸻FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Stay informed on current events, visit www.NaturalNews.com  - Memorial Day Message and Introduction to Energy Technology (0:02) - Impact of the War in Iran on Energy Technology (3:59) - Commercialization and Future of LENR Technology (8:00) - Challenges and Opportunities in Energy Transition (9:11) - Memorial Day Sale and Store Updates (9:34) - Translation Projects and Future Plans (12:26) - Impact of the War in Iran on Global Energy Supply (14:56) - Advancements in Battery Technology (36:37) - Challenges in Data Center Development (56:16) - Potential for Decentralized Power Production (1:17:59) - X AI's Tactics and Community Pushback (1:18:16) - Health Impact of Gas Turbines (1:20:33) - Community Action and Activist Movements (1:22:41) - Technological Overkill and Data Center Viability (1:29:53) - China's Role in Data Center Scaling (1:33:58) - Digital ID and Surveillance Infrastructure (1:37:57) - The Spiritual and Practical Implications of Data Centers (1:46:01) - The Role of Decentralized Technology (1:53:12) - The Impact of Social Media and Addictions (2:06:28) - The Importance of Natural Dopamine Support (2:11:30) - Impact of Media and Pharma on Public Perception (2:33:51) - Awareness and Establishment Resistance (2:36:03) - Historical and Current Pharma Scandals (2:39:20) - Natural Solutions and Superfoods (2:41:33) - Impact of Toxic Ingredients and Seed Oils (2:45:28) - Glyphosate and Corporate Influence (2:53:25) - Personal Responsibility and Health Awareness (2:57:10) - Addiction Rescue Course and Dopamine Revolution (3:00:05) - Memorial Day Sale and Health Ranger Store (3:03:35) - Final Thoughts and Encouragement (3:08:55) Watch more independent videos at http://www.brighteon.com/channel/hrreport  ▶️ Support our mission by shopping at the Health Ranger Store - https://www.healthrangerstore.com ▶️ Check out exclusive deals and special offers at https://rangerdeals.com ▶️ Sign up for our newsletter to stay informed: https://www.naturalnews.com/Readerregistration.html Watch more exclusive videos here: